RBC Capital Initiates Coverage on Genzyme (GENZ) with an Outperform
GENZ Hot Sheet
Rating Summary:1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
RBC Capital initiates coverage on Genzyme (Nasdaq: GENZ) with an Outperform rating.
To see more analyst ratings on GENZ Click Here.
Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology.
To see more analyst ratings on GENZ Click Here.
Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology.
You May Also Be Interested In
- UPDATE: Auriga Starts Akorn (AKRX) at Buy; Unique Product Portfolio with Limited Competition
- Cowen Starts MELA Sciences (MELA) at Outperform
- ThinkEquity Starts Cavium Networks (CAVM) at Hold
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
